MedTrace Logo

Study of Oral PG-116800 Following a Heart Attack

NCT00067236 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 253

Last updated 2011-11-04

Study results available
· View outcomes & findings →

Summary

The main purpose of the study is to test whether a possible new drug (called PG-116800) can prevent some of the damage to heart muscle in patients who have had a heart attack. The study will also supply information regarding possible uses of this compound in cardiovascular disease.

Conditions

Interventions

DRUG

PG-116800 (given as PG-530742)

200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days

DRUG

Placebo tablet

placebo tablet, twice a day for 90 days

Sponsors & Collaborators

  • Procter and Gamble

    lead INDUSTRY

Principal Investigators

  • Jose Brum, MD · Procter and Gamble

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2004-12-31
Completion
2004-12-31

Countries

  • United States
  • Canada
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00067236 on ClinicalTrials.gov